The results showed that the SGLT2 inhibitors lower blood glucose from 2 h after the first dose and improve blood glucose variation by week 1 after start of the treatment. Furthermore, SGLT2 inhibitors did not alter the incidence of hypoglycemic episodes at week 1, suggesting that SGLT2 protects against severe hypoglycemia by inhibiting urinary glucose excretion (Diabetology & Metabolic Syndrome)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Reduction of depressive symptoms predicts improved glycaemic control: Secondary results from the DIAMOS study
The findings suggest that reduction of depressive symptoms can explain improved glycaemic control. Behavioural treatments might aim to improve both affective and glycaemic outcomes (Journal of Diabetes and Its Complications)
The Role of Epigenetics in Type 1 Diabetes
Epigenomics remains in its infancy, and we anticipate further studies will define how the interaction of genetic and non-genetic effects induces tissue-specific destruction and enhances our ability to predict, and possibly even modify that process (Current Diabetes Reports)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming (Diabetologia)
Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes
Among adults with type 2 diabetes diagnosed for less than 10 years, a lifestyle intervention compared with standard care resulted in a change in glycemic control that did not reach the criterion for equivalence, but was in a direction consistent with benefit. Further research is needed to assess superiority, as well as generalizability and durability of findings )JAMA)
A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data
All currently available diabetes medications are approved for adults with T2DM with a remarkably limited number for adults with T1DM and children with T1DM or T2DM. The incorporation of emerging data on cardiovascular outcomes in FDA drug labels is expected to influence the way physicians treat patients with diabetes (Journal of Diabetes and Its Complications)
Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review
To our knowledge, this is the first SLR on the epidemiology of DKA in T1D adults. Despite an increasing prevalence of T1D in recent years, DKA in adults has been poorly characterised. In an era when the benefit–risk profiles of new antidiabetic therapies are being evaluated, including the potential risk of DKA, there is a clear need to better elucidate the expected rate of DKA among T1D adults. (BMJ)
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1RA and DPP4 Therapies in Patients With Type 2 Diabetes
Poor medication adherence is primarily why RW effectiveness is significantly less than RCT efficacy, suggesting an urgent need to effectively address adherence among patients with type 2 diabetes (Diabetes Care)
Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes
The present findings suggest that self-compassion may be a parsimonious and suitable intervention target. Future interventions and consultations with medical professionals may benefit from fostering self-compassion in adults with diabetes mellitus (Diabetic Medicine)
The role of bariatric surgery to treat diabetes: current challenges and perspectives
The gastrointestinal tract represents a meaningful target to treat T2DM. Surgical operations with intestinal diversion have consistently shown the capacity to improve glucose homeostasis by modulating gut hormones, beyond reducing energy intake and body weight. LAGB, SG, RYGB and BPD are the four best standardized surgical procedures (BMC Endocrine Disorders)
Screening for sexual dissatisfaction among people with type 2 diabetes in primary care
One third of people with T2DM is sexually dissatisfied and more than half of these people report a need for help. The BSSC could be used a tool to proactively identify sexually dissatisfied people in primary care (Diabetes and Its Complications)
There really is no such thing as mild diabetes: a new perspective on an old idea
This low-risk at or near target population has become ‘hidden in plain sight’ and the significant contribution to the overall population risk and cost completely overlooked (British Journal of Diabetes)
Glucose-lowering drugs: balancing risks and benefits
Yet more evidence in support of a class effect of SGLT2 inhibitors (The Lancet Diabetes & Endocrinology)
Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization
US patients with T2D who experienced hypoglycemia within 6 months of basal insulin initiation were more likely to discontinue treatment, accompanied by a greater healthcare burden (Advances in Therapy)
Impact of A National Collaborative Care Initiative for Patients With Depression and Diabetes or Cardiovascular Disease
COMPASS was successfully spread across diverse care systems and demonstrated improved outcomes for complex patients with previously uncontrolled chronic disease. Future large-scale implementation projects should create robust processes to identify and reduce expected variation in implementation to consistently provide improved care (Journal of Lifelong Learning in Psychiatry)
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies
Initial combination therapy with dapagliflozin 5 or 10 mg/d and metformin improved quality measures relevant to clinical outcomes and diabetes care (Risk Management and Healthcare Policy)
Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic β-cells in Patients with Type 2 Diabetes
Dapagliflozin improved β-cell responses to incretin hormones as well as glucose during the hyperglycemic clamp in patients with inadequately controlled T2DM (Diabetes, Obesity and Metabolism)
Renal glucose metabolism in normal physiological conditions and in diabetes
The kidney plays a direct and significant role in glucose homeostasis via gluconeogenesis, glucose uptake and utilization, and glucose reabsorption from glomerular filtrate … (Diabetes Research and Clinical Practice)
Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement
Neonatal diabetes can be detected on day 5 of life, preceding conventional diagnosis in most cases. Earlier diagnosis by systematic screening could lead to prompt genetic diagnosis and targeted treatment, thereby avoiding the most severe sequelae of hyperglycaemia in neonates (Diabetologia)
Screening for sexual dissatisfaction among people with type 2 diabetes in primary care
One third of people with T2DM is sexually dissatisfied and more than half of these people report a need for help. The BSSC could be used a tool to proactively identify sexually dissatisfied people in primary care (Journal of Diabetes and Its Complications)
- 1
- 2
- 3
- …
- 145
- Next Page »
This site complies with the 